Fig. 1: Survival outcome of patients with myelodysplastic syndrome (MDS) progressing on hypomethylating agents (HMA). | Blood Cancer Journal

Fig. 1: Survival outcome of patients with myelodysplastic syndrome (MDS) progressing on hypomethylating agents (HMA).

From: Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs

Fig. 1

(A) Kaplan Meier survival curve after HMA progression based on different therapies, (B) in patients with complete remission (CR) receiving stem cell transplantation (SCT) vs patient in CR and no SCT, (C) in MDS-EB1, MDS-EB2 and AML (D) in TP53 mutated patients (E) in patients with TP53 mutated and/or complex cytogenetics receiving HMA/low dose cytarabine (LDAC) plus venetoclax versus CPX-351.

Back to article page